Despite high rates of vaccination with acellular pertussis (aP) vaccines, the incidence of Bordetella pertussis infections is on the rise in the United States and other high-income countries [1] . Severe pertussis cases are characterized by intense and paroxysmal cough associated with posttussive vomiting, inspiratory whoop, cyanosis, and leukocytosis [2, 3] . Because the first routine pertussis vaccination occurs at 6-8 weeks of age, infants <2 months of age have the highest rate of serious clinical complications requiring hospitalization and the highest mortality rate [4, 5] . Paroxysmal fits in very young infants are characterized by gagging, gasping, bradycardia, cyanosis, and vomiting [6] . Apneic episodes following paroxysmal fits are common [6] . Severe and fatal pertussis in young infants is associated with extreme leukocytosis, pulmonary hypertension, and pneumonia [6, 7] . Maternal immunization has emerged as the optimal strategy to protect newborns from pertussis illness during the first months of life. Numerous studies have demonstrated that maternal vaccination with licensed aP vaccines during pregnancy results in elevated B. pertussis-specific antibody titers in newborns that are presumed to be protective [8] [9] [10] [11] [12] . Based largely on evidence of safety and increased antibody titers in infants, the Advisory Committee on Immunization Practices and the United Kingdom Department of Health recommended that all pregnant women be offered pertussis vaccine to protect newborns from pertussis exposure [13, 14] . Following adoption of maternal vaccination, several studies in the United Kingdom and the United States reported high levels of efficacy of maternal vaccination for the prevention of laboratory-confirmed pertussis in infants [15] [16] [17] [18] [19] . Supportive data were provided by a study that used the baboon model of pertussis to demonstrate protection of newborn baboons born to mothers vaccinated during pregnancy with aP vaccine [20] .
The baboon model of pertussis developed in our laboratory accurately reproduces severe clinical pertussis [21] [22] [23] . In addition to providing an excellent model of pertussis, the baboon has proven to be a relevant model for reproductive studies [24, 25] . Baboons possess the same 4 immunoglobulin G (IgG) subclasses as humans [26] and transplacental transfer of IgG from mother to fetus occurs as in humans [27, 28] . This model provides a unique opportunity to characterize the mechanisms underlying the protection conferred following maternal vaccination and to evaluate the protection conferred by alternative vaccine formulations.
In the previous study, newborn baboons born to vaccinated mothers were protected from clinical disease; however, colonization of the upper respiratory tract was not reduced relative to that in infant baboons born to unvaccinated mothers [20] . The failure of maternal vaccination with aP vaccines to reduce bacterial colonization of the infant airway suggested that maternal antibodies against filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae (FIM) did not contribute to the observed protection. These bacterial proteins were included in aP vaccines because they are thought to be important for colonization and carriage. We hypothesized that the observed protection of infants from disease was due to the action of maternal, toxin-neutralizing, anti-pertussis toxin (PT) antibodies. If this hypothesis is correct, maternal vaccination with a monocomponent aP vaccine, composed solely of pertussis toxoid (PTx), would be sufficient to protect infants from disease.
In this study, we evaluated the protection conferred to infant baboons by maternal vaccination with a monocomponent PTx vaccine. Infant baboons born to vaccinated mothers and those born to unvaccinated mothers were exposed to B. pertussis at 5-6 weeks of age. There was no significant difference in bacterial colonization of the airway between infants born to vaccinated mothers and those born to unvaccinated mothers. Infant baboons born to unvaccinated mothers developed severe pertussis. In contrast, infants born to mothers vaccinated with the monocomponent PTx vaccine showed no signs of disease, demonstrating that maternal vaccination with PTx alone is sufficient to protect infant baboons from pertussis.
METHODS

Ethics Statement
All animal procedures were performed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International in accordance with protocols approved by the University of Oklahoma Health Sciences Center Animal Care and Use Committee and in accordance with the principles outlined in the Guide for the Care and Use of Laboratory Animals, produced by the Institute for Laboratory Animal Resources, National Research Council.
Animals
Eight adult female baboons were acquired from a specific-pathogen-free baboon colony (Oklahoma Baboon Research Resource, Oklahoma City) [28] . They had no known exposure to Bordetella species and were free of titers to PT prior to vaccination. Infant baboons were born naturally to their mothers in the colony and transferred to the nonhuman primate nursery on the day of birth to provide more-standardized care and monitoring throughout the studies. Neonates and infants in the nursery were hand-fed a human baby formula (Similac) ad libitum. Once inoculated with B. pertussis, they were housed in animal biosafety level 2+ housing until at least 2 nasopharyngeal washes were B. pertussis negative.
Bacterial Strains and Media
B. pertussis strain D420 was grown on Bordet-Gengou agar plates prepared with Bordet-Gengou agar (Becton Dickinson, Sparks, MD) containing 1% proteose peptone (Becton Dickinson) and 15% defibrinated sheep blood. Regan-Lowe plates were prepared from Regan-Lowe charcoal agar base (Becton Dickinson) with 10% defibrinated sheep blood and 40 µg/mL cephalexin.
Vaccine
Pharmaceutical-grade monocomponent PTx vaccine was provided by MassBiologics (Mattapan, MA). The single-component PTx was produced from PT purified from fermentation cultures of B. pertussis and then inactivated with hydrogen peroxide. The PTx was adsorbed to aluminum hydroxide. The vaccine was formulated at 40 μg/mL of PTx and 1 mg/mL of Alhydrogel. The baboon dose was 0.5 ml administered intramuscularly.
Inoculation
All infant baboons were challenged between 5 and 6 weeks of age. Inocula were prepared to a concentration of 10 8 bacteria/ mL as previously described [21] . Baboons were anesthetized with 10-15 mg/kg ketamine administered intramuscularly. The pharynx was swabbed with 2% lidocaine solution, and animals were intubated using a 2-3-mm (inner diameter) endotracheal tube to deliver 0.5 mL of the inoculum to the proximal trachea. In addition, a 22-gauge, 3.2-cm Teflon intravenous catheter (Abbocath) was used to deliver 0.25 mL of inoculum to both nasal cavities. Animals were placed in a sitting position for 3 minutes, returned to their cages, and observed until they recovered from anesthesia.
Evaluation of Animals
Infants were observed twice daily, and their clinical condition and behavior was noted. Case notes were reviewed by 6 blinded researchers, and an overall clinical score based on the severity and duration of symptoms was assigned to each animal independently by each researcher. For biological sample collection, baboons were anesthetized with ketamine twice per week following inoculation. Whole-blood specimens were collected and evaluated for the number of circulating white blood cells, by complete blood count (CBC). Each nasal cavity was flushed with 0.5 mL of phosphate-buffered saline, using a 22 gauge/3.2-cm intravenous catheter. The recovered nasopharyngeal washes from both nares were combined, and 100 µL of the recovered sample was divided and plated onto 2 Regan-Lowe plates. The number of B. pertussis colony-forming units (CFUs) per plate was recorded after incubation at 37 o C for 4-5 days.
Serum Antibody Enzyme-Linked Immunosorbent Assay (ELISA)
Serum IgG for PT, FHA, FIM, and PRN was detected using serum antibody ELISA as described previously [20, 29] . Briefly, Nunc 96-well plates (Fisher Scientific, Rochester, NY) were coated overnight with 2 µg/mL PT, 0.5 µg/mL FHA, 0.2 µg/mL FIM 2/3, or 2 µg/mL PRN (List Biologicals, Campbell, CA). Horseradish peroxidase-conjugated goat anti-monkey IgG polyclonal secondary antibody (AbD Serotec [catalog code AAI42P]; Raleigh, NC) was used to measure serum IgG level for each antigen. The serum antibody was analyzed against a standard curve to assign international units for PT, FHA, and PRN in each sample and relative units for FIM. The standard curve was prepared for each plate by making a serial dilution of the World Health Organization international standard B. pertussis antiserum (NIBSC, Hertfordshire, England).
Statistical Analysis
Statistical analysis was determined using a 2-tailed Student t test assessed by GraphPad Prism software. Results are shown as mean values ± standard deviations for each sample. Antibody data were normalized by log transformation before analysis.
RESULTS
Pregnant baboons were vaccinated with a monocomponent, PTx-only aP vaccine. These baboons were not previously vaccinated with pertussis vaccine and were sourced from a colony with no known Bordetella exposure. Therefore, the response to vaccination in these pregnant animals was a primary response rather than a booster response and was expected to be low. Because of the uncertainty that protection would be achieved with a single vaccination of a naive animal, the first animal was vaccinated twice during pregnancy, on day 60 and day 125 of gestation, and the second animal was vaccinated a single time, on day 125. The infants born to both animals were similarly protected, so the remaining 2 animals in the vaccine group were vaccinated only once, on day 125 of gestation. The 4 infants born to PTx-vaccinated mothers and 4 infants born to unvaccinated mothers were challenged with B. pertussis strain D420 at 5 weeks of age, and bacterial loads in the airway were evaluated by determining the number of CFUs present in nasopharyngeal washes following challenge. Infants born to unvaccinated mothers were heavily colonized, with peak levels between 10 7 and 10 10 CFU/mL (Figure 1) . Infants born to the 4 PTx-vaccinated mothers had peak values between 10 6 and 10 8 CFU/mL and maintained those high levels for 2 weeks (Figure 1) . After day 14, CFUs gradually declined, and the animals subsequently cleared the infection between days 24 and 28 after infection.
Following challenge, all 4 animals born to unvaccinated mothers developed significant disease. Three were euthanized owing to the severity of their clinical disease. Clinical signs, beginning between days 3 and 7 after exposure, observed in these 3 infants started with infrequent coughing and progressed to frequent paroxysmal coughing that led to extreme lethargy. At the peak of illness, they exhibited tachypnea, dyspnea, tachycardia, and cyanotic mucous membranes. Furthermore, they exhibited anorexia with little to no effort given to obtaining food. The fourth infant in this group exhibited clinical signs of mild disease that included slight anorexia, infrequent coughing, and a mild decrease in activity. This baboon was obviously sick but did not reach the criteria for euthanasia. The significant outward signs of disease observed in these animals were reflected in the high clinical score assigned (Figure 2A) . The 3 infants born to Infant baboons born to mothers vaccinated with the monocomponent PTx vaccine during pregnancy (blue; n = 4) or to unvaccinated mothers (black; n = 4) were directly challenged with B. pertussis at 5-6 weeks of age. Colonization was monitored by quantifying B. pertussis colony-forming units (CFUs) in nasopharyngeal washes, with a limit of detection of 10 CFUs/mL. Three of 4 infants born to unvaccinated mothers were euthanized owing to the severity of disease and were lost to follow-up. unvaccinated mothers with severe clinical symptoms also had highly elevated white blood cell counts, with peak values between 83 000 and 110 000 cells/µL. The fourth infant, with milder clinical symptoms, had a correspondingly lower peak white blood cell count of 40 000 cells/µL. In contrast, all 4 infants born to mothers vaccinated with the monocomponent PTx vaccine remained healthy throughout the 4 weeks following challenge. Despite heavy nasopharyngeal colonization (Figure 1 ), they remained active and alert. They were assigned clinical scores between 0 and 1, reflecting the lack of outward signs of disease (Figure 2A ). The fold change in the number of circulating WBCs relative to preinfection baseline values was low in the infants born to vaccinated mothers relative to the fold change observed in infants born to unvaccinated mothers ( Figure 2B) . To evaluate the level of immune responses to PT and B. pertussis antigens other than PT, we determined the titers present in the infant prechallenge sera for PT, FHA, PRN, and FIM by ELISA. FHA, PRN, and FIM were selected because our laboratory has established, well-characterized ELISAs for those antigens. We reasoned that a lack of response to these antigens would indicate that the PTx-only vaccine is relatively free of contaminating B. pertussis antigens. All 4 infants born to the vaccinated mothers had elevated anti-PT titers relative to infants born to unvaccinated mothers. One of the 4 had a very high anti-PT titer. This was not the infant whose mother received 2 vaccinations during pregnancy. It is not known why this infant's mother responded so strongly to PTx. The infant did not exhibit unusually high titers to the other 3 antigens tested, ruling out the concern that this animal's mother had been previously exposed to Bordetella organisms. All 4 animals born to unvaccinated mothers exhibited very low anti-PT antibody titers (Figure 3) . The 4 infants born to vaccinated mothers had low antibody titers to FHA, PRN, and FIM that were comparable to the titers measured in the infants born to unvaccinated mothers (Figure 3) .
DISCUSSION
In the previous baboon maternal vaccination study, baboons were vaccinated during pregnancy with US-licensed aP vaccines that contained PT, FHA, and PRN (Infanrix) or PT, FHA, PRN, and FIM (Daptacel) [20] . All infants born to vaccinated mothers were protected from disease, but the magnitude and duration of bacterial colonization of the airway were indistinguishable between the infants born to vaccinated mothers and the infants born to unvaccinated mothers. Similarly, in this study, infants born to mothers vaccinated with the monocomponent PTx vaccine were protected from disease, but the magnitude and duration of infection were not reduced relative to animals born to vaccinated mothers. The magnitude and duration of bacterial colonization of the airway observed in all animals in this study were similar to those observed in unvaccinated and aP-vaccinated baboons in previously published studies. This result is consistent with previous results demonstrating that vaccination with the aP vaccine does not protect against colonization.
The vaccines used in maternal vaccination programs (ie, Tdap vaccines) are reduced-dose adult booster vaccines that contain PT, FHA, and PRN or PT, FHA, PRN, and FIM, depending on the manufacturer. In addition to these B. pertussis antigens, all include Clostridium tetanus toxoid and Corynebacterium diphtheriae toxoid. The protection against pertussis conferred by maternal vaccination with Tdap is presumed to be largely due to the transplacental transfer of IgG to the infant and/or due to secretory immunoglobulin A and IgG transferred in breast milk [30] . It is thought that the role of FHA, FIM, and PRN in pathogenesis is to contribute to bacterial adherence to host tissues and to resist clearance by neutrophils [2, 31] . Antibodies against FHA, FIM, or PRN would most likely confer protection by reducing the magnitude or duration of infection in the airway. As a reduction in colonization was not observed in the previous baboon maternal vaccination study, the observed protection against disease was most likely due to the transfer of maternal toxin-neutralizing antibodies that blocked the actions of PT in the infant. This is consistent with our understanding of B. pertussis pathogenesis. Very-high-level leukocytosis is strongly associated with poor outcome in newborns infected with B. pertussis, and leukocytosis is the result of direct action of PT. In this study, the protection conferred by maternal vaccination with a monocomponent PTx vaccine was evaluated. Despite the relatively low anti-PTx titers in 3 of 4 infants born to mothers vaccinated with the monocomponent PTx vaccine, all 4 infants were protected from disease following exposure to B. pertussis. In contrast, all 4 infants born to unvaccinated mothers experienced significant disease. The possibility that responses to pertussis antigens other than PTx, which were present in trace amounts in the vaccine, contributed to protection cannot be ruled out. To evaluate responses to antigens not included in the PTx vaccine, we evaluated antibody responses to those antigens for which we had well-established ELISAs. In this study, all 4 vaccinated infants had titers for FHA, PRN, and FIM comparable to values observed in the unvaccinated animals indicating that the PTx monocomponent vaccine did not elicit significant responses to antigens other than PT. In contrast, the anti-PT titers in all 4 infants born to vaccinated mothers were higher than the anti-PT titers in the unvaccinated animals. All 4 infants that were protected against disease had PT titers higher than the 4 infants that were not protected. These results suggest that the protection observed in the infants born to vaccinated mothers was due to the provision of toxin-neutralizing (anti-PT) antibodies. The results of this study support the hypothesis that the most severe symptoms associated with pertussis are due to the action of PT and can be blocked by the provision of toxin-neutralizing antibodies. The global burden of pertussis is difficult to assess. In lowand middle-income countries (LMICs), the surveillance for pertussis is based solely on clinical diagnosis of disease [32] . Pertussis is often misdiagnosed when relying on diagnosis based on symptoms, particularly in young infants, in whom cough is not always observed or is atypical. Pertussis in as many as 90% of infants with cases may be undiagnosed in the absence of active surveillance and laboratory diagnostics [33, 34] . Pertussis deaths in settings where maternal vaccination programs have been introduced have dropped dramatically [15] . Expansion of maternal vaccination to LMICs has the potential to dramatically decrease the infant mortality burden due to pertussis in those countries, but this would only be cost-effective in many LMICs if the vaccine can be obtained at low cost [35] . By reducing the cost of production of the pertussis component of a combined tetanus-pertussis adult booster vaccine, the exclusion of pertussis antigens other than PTx may facilitate the extension of maternal vaccination for pertussis in low-income countries.
Studies evaluating the impact of maternal vaccination on immune responses to the childhood immunizations given at 2, 4, and 6 months of age have produced conflicting results [36] . Some have shown no impact on responses, while others have demonstrated mild blunting of responses to antigens present in the maternal vaccine. In all of those studies, no difference was observed in the responses following the fourth dose, delivered at 12 months. There is no evidence that this blunting is clinically significant. However, one advantage of a maternal vaccine containing only tetanus and PTx would be the avoidance of blunting of responses to other antigens included in the infant vaccination series.
Although it is important to be conservative in interpreting the results of this study and extrapolating them to humans, this study demonstrated, in a highly relevant animal model, that vaccination during pregnancy with a monocomponent PTx vaccine was sufficient to protect newborns from disease. The response to vaccination required to confer protection appears to be easily achievable by a single vaccination in previously unvaccinated adult baboons. It is likely that stronger responses would be observed in human mothers who have a history of childhood pertussis vaccination and/or have had exposure to the disease. 
